California Dreaming: Long-Term Messages From Governor’s Rx Price Actions
Immediate impact of California Governor Newsom’s directive on drug pricing unlikely to be dramatic, but there are important long-term messages for biopharma companies to weigh.
You may also be interested in...
Michigan follows Oklahoma in gaining approval to negotiate supplemental rebates in the context of value-based contracts for drugs. Oklahoma now has four novel contracts in place.
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.
Whether CME for pain management has the intended impact on prescribing is likely focus of new ‘suite of studies’ intended to assess the opioid REMS program. The challenges for FDA include teasing out the impact of the risk management program amid all the other public health efforts on opioids.